A Recent Achievement In the Discovery and Development of Novel Targets for the Treatment of Type-2 Diabetes Mellitus

References

• Zheng Y, Ley SH, Hu FB. Global etiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Aynalem SB, Zeleke AJ. Prevalence of diabetes mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman town, Southwest Ethiopia, 2016: a cross-sectional study. Int J Endocrinol. 2018;2018:1–7. doi:10.1155/2018/9317987
   Web of Science ®Google Scholar
• Xu Y, Rubin BR, Orme CM, et al. Dual-mode of insulin action controls GLUT4 vesicle exocytosis. J Cell Biol. 2011;193(4):643–653. doi:10.1083/jcb.201008135
   Web of Science ®Google Scholar
• Jaldin-Fincati JR, Pavarotti M, Frendo-Cumbo S, Bilan PJ, Klip A. Update on GLUT4 vesicle traffic: a cornerstone of insulin action. Trends Endocrinol Metab. 2017;28(8):597–611. doi:10.1016/j.tem.2017.05.002
   PubMed Web of Science ®Google Scholar
• Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122. doi:10.1186/s12933-018-0762-4
   PubMed Web of Science ®Google Scholar
• Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: a mini-review. Curr Diabetes Rev. 2017;13(1):3–10. doi:10.2174/1573399812666151016101622
   PubMed Web of Science ®Google Scholar
• Moon MK, Hur KY, Ko SH, et al. Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Diabetes Metab J. 2017;41(5):357–366. doi:10.4093/dmj.2017.41.5.357
   Web of Science ®Google Scholar
• Chaudhury A, Duvoor C, Dendi R, et al. Clinical review of anti-diabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017;8:6. doi:10.3389/fendo.2017.00006
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–399. doi:10.7326/0003-4819-147-6-200709180-00178
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi:10.1007/s00125-012-2534-0
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr. 2014;27(2):100–112. doi:10.2337/diaspect.27.2.100
   PubMedGoogle Scholar
• Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging. 2013;30(7):527–547. doi:10.1007/s40266-013-0081-0
   Web of Science ®Google Scholar
• Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, Sosale A, Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci. 2013;9(5):936. doi:10.5114/aoms.2013.34991
   Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4.
   PubMedGoogle Scholar
• Abbas AS, Dehbi HM, Ray KK. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes Metab. 2016;18(3):295–299. doi:10.1111/dom.12595
   PubMed Web of Science ®Google Scholar
• Nanjan MJ, Mohammed M, Kumar BP, Chandrasekar MJ. Thiazolidinediones as anti-diabetic agents: a critical review. Bioorg Chem. 2018;1(77):548–567. doi:10.1016/j.bioorg.2018.02.009
   Web of Science ®Google Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. doi:10.1007/s00125-017-4336-x
   PubMed Web of Science ®Google Scholar
• Hücking K, Kostic Z, Pox C, et al. α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7–36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med. 2005;22(4):470–476. doi:10.1111/dme.2005.22.issue-4
   Web of Science ®Google Scholar
• Jorsal T, Rungby J, Knop FK, Vilsbøll T. GLP-1 and amylin in the treatment of obesity. Curr Diab Rep. 2016;16(1):1. doi:10.1007/s11892-015-0693-3
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: a systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783–794. doi:10.1111/dom.12670
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12(5):384–392. doi:10.1111/dom.2010.12.issue-5
   PubMed Web of Science ®Google Scholar
• Lamos EM, Levitt DL, Munir KM. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters. Prim Care Diabetes. 2016;10(1):60–65. doi:10.1016/j.pcd.2015.10.008
   Web of Science ®Google Scholar
• Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009;11(1):53–59. doi:10.1111/dom.2009.11.issue-1
   PubMed Web of Science ®Google Scholar
• Brauner-Osborne H, Wellendorph P, Jensen AA. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets. 2007;8(1):169–184. doi:10.2174/138945007779315614
   Web of Science ®Google Scholar
• Ahren B. Islet G protein-coupled receptors as potential targets for the treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8(5):369. doi:10.1038/nrd2782
   PubMed Web of Science ®Google Scholar
• Lee Kennedy R, Vangaveti V, Jarrod G, Shashidhar V, Shashidhar V, Baune BT. Free fatty acid receptors: emerging targets for the treatment of diabetes and its complications. Ther Adv Endocrinol Metab. 2010;1(4):165–175. doi:10.1177/2042018810381066
   Google Scholar
• Ichimura A, Hasegawa S, Kasubuchi M, Kimura I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol. 2014;6(5):236.
   Google Scholar
• Li Z, Qiu Q, Geng X, Yang J, Huang W, Qian H. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs. 2016;25(8):871–890. doi:10.1080/13543784.2016.1189530
   PubMed Web of Science ®Google Scholar
• Defossa E, Wagner M. Recent developments in the discovery of FFA1 receptor agonists as a novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett. 2014;24(14):2991–3000. doi:10.1016/j.bmcl.2014.05.019
   PubMed Web of Science ®Google Scholar
• Yang JW, Kim HS, Choi YW, Kim YM. Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes Obes Metab. 2018;20(2):257–269. doi:10.1111/dom.13062
   Web of Science ®Google Scholar
• Liu Y, Zhang Q, Chen LH, et al. Design and synthesis of 2-alkylpyrimidine-4, 6-diol and 6-alkylpyridine-2, 4-diol as potent GPR84 agonists. ACS Med Chem Lett. 2016;7(6):579–583. doi:10.1021/acsmedchemlett.6b00025
   Web of Science ®Google Scholar
• Shehata MA, Christensen HB, Isberg V, et al. Identification of the first surrogate agonists for the G protein-coupled receptor GPR132. RSC Adv. 2015;5(60):48551–48557. doi:10.1039/C5RA04804D
   Web of Science ®Google Scholar
• Sprecher D, Maxwell M, Goodman J, et al. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist. Eur J Pharmacol. 2015;756:1–7. doi:10.1016/j.ejphar.2015.01.051
   Web of Science ®Google Scholar
• Milligan G. G protein-coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35. Br J Pharmacol. 2018;175(13):2543–2553. doi:10.1111/bph.v175.13
   Web of Science ®Google Scholar
• Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, Chang CJ. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonists, in the regulation of glucose homeostasis and insulin sensitivity. Am J Physiol Endocrinol Metab. 2013;304(6):E668–76. doi:10.1152/ajpendo.00419.2012
   Web of Science ®Google Scholar
• Wasserman DH. Four grams of glucose. Am J Physiol Endocrinol Metab. 2009;296(1):E11–E21. doi:10.1152/ajpendo.90563.2008
   PubMed Web of Science ®Google Scholar
• Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721–766. doi:10.1152/physrev.00025.2016
   PubMed Web of Science ®Google Scholar
• Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296(3):E415–21. doi:10.1152/ajpendo.90887.2008
   Web of Science ®Google Scholar
• Ouhilal S, Vuguin P, Cui L, et al. Hypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance. Am J Physiol Endocrinol Metab. 2011;302(5):522–531. doi:10.1152/ajpendo.00420.2011
   Web of Science ®Google Scholar
• Lotfy M, Kalasz H, Szalai G, Singh J, Adeghate E. Recent progress in the use of glucagon and glucagon receptor antagonists in the treatment of diabetes mellitus. Open Med Chem J. 2014;8:28. doi:10.2174/1874104501408010028
   PubMedGoogle Scholar
• Scheen AJ, Paquot N, Lefèbvre PJ. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. Expert Opin Investig Drugs. 2017;26(12):1373–1389. doi:10.1080/13543784.2017.1395020
   PubMed Web of Science ®Google Scholar
• Lei L, Liu S, Li Y, et al. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection. Eur J Pharmacol. 2018;826:17–23. doi:10.1016/j.ejphar.2018.02.036
   Web of Science ®Google Scholar
• Pal M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov Today. 2009;14(15–16):784–792. doi:10.1016/j.drudis.2009.05.013
   PubMed Web of Science ®Google Scholar
• Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators. J Diabetes Investig. 2015;6(2):124–132. doi:10.1111/jdi.2015.6.issue-2
   PubMed Web of Science ®Google Scholar
• Anık A, Çatlı G, Abacı A, Böber E. Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab. 2015;28(3–4):251–263. doi:10.1515/jpem-2014-0384
   PubMed Web of Science ®Google Scholar
• Bhuniya D, Kapkoti SG, Warrier SJ, Kukrejka G, Mavinahalli NJ, Palle PV Pyrrole-2-carboxamide derivatives as glucokinase activators, their process, and pharmaceutical application. United States patent US 8,299,115. 2012 Oct 30.
   Google Scholar
• Scheen AJ. Investigational insulin secretagogues for type 2 diabetes. Expert Opin Investig Drugs. 2016;25(4):405–422. doi:10.1517/13543784.2016.1152260
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Chijiwa H, et al. Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica. 2017;47(5):382–393. doi:10.1080/00498254.2016.1199063
   PubMed Web of Science ®Google Scholar
• Zhu XX, Zhu DL, Li XY, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018;20(9):2113–2120. doi:10.1111/dom.13338
   PubMed Web of Science ®Google Scholar
• Tsumura Y, Tsushima Y, Tamura A, et al. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models. PLoS One. 2017;12(2):e0172252. doi:10.1371/journal.pone.0172252
   Web of Science ®Google Scholar
• Vella A, Freeman JL, Dunn I, Keller K, Buse JB, Valcarce C. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019;11:475. doi:10.1126/scitranslmed.aau3441
   Web of Science ®Google Scholar
• Kubota K, Inaba SI, Nakano R, et al. Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917. Pharmacol Res Perspect. 2015;3(3):e00138. doi:10.1002/prp2.138
   Google Scholar
• Kaur R, Dahiya L, Kumar M. Fructose-1, 6-bisphosphatase inhibitors: a new valid approach for management of type 2 diabetes mellitus. Eur J Med Chem. 2017;141:473–505. doi:10.1016/j.ejmech.2017.09.029
   PubMed Web of Science ®Google Scholar
• Yip J, Geng X, Shen J, Ding Y. Cerebral gluconeogenesis and diseases. Front Pharmacol. 2017;4(7):521.
   Google Scholar
• Gizak A, Duda P, Wisniewski J, Rakus D. Fructose-1, 6-bisphosphatase: from a glucose metabolism enzyme to the multifaceted regulator of cell fate. Adv Biol Regul. 2019;72:41–50. doi:10.1016/j.jbior.2019.03.001
   Google Scholar
• Teo CF, Wollaston-Hayden EE, Wells L. Hexosamine flux, the O-GlcNAc modification, and the development of insulin resistance in adipocytes. Mol Cell Endocrinol. 2010;318(1–2):44–53. doi:10.1016/j.mce.2009.09.022
   Web of Science ®Google Scholar
• Nakaishi Y, Bando M, Shimizu H, et al. Structural analysis of human glutamine: fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetes. FEBS Lett. 2009;583(1):163–167. doi:10.1016/j.febslet.2008.11.041
   PubMed Web of Science ®Google Scholar
• Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab. 2006;290(1):E1–E8. doi:10.1152/ajpendo.00329.2005
   PubMed Web of Science ®Google Scholar
• Jeong JY, Jeoung NH, Park KG, Lee IK. Transcriptional regulation of pyruvate dehydrogenase kinase. Diabetes Metab J. 2012;36(5):328–335. doi:10.4093/dmj.2012.36.5.328
   PubMedGoogle Scholar
• Mayers RM, Leighton B, Kilgour E. PDH kinase inhibitors: a novel therapy for Type II diabetes? 2005:367–370.
   Google Scholar
• Hasan N, Mujahid M, Badruddeen MK, et al. J Pharm Res. 2017;6(2).
   Google Scholar
• Singh Grewal A, Bhardwaj S, Pandita D, Lather V, Singh Sekhon B. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2015;16(2):120–162. doi:10.2174/1389557515666150909143737
   Web of Science ®Google Scholar
• Ramana KV. Aldose reductase: new insights for an old enzyme. Biomol Concepts. 2011;2(1–2):103–114. doi:10.1515/bmc.2011.002
   PubMedGoogle Scholar
• Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem. 2003;10(15):1329–1352. doi:10.2174/0929867033457377
   PubMed Web of Science ®Google Scholar
• Iyer S, Murthy K, Parton Z, et al. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. bioRxiv. 2019;Jan:626697.
   Google Scholar
• Zhao C, Wu Y, Yang C, Liu B, Huang Y. Hypotensive, hypoglycaemic and hypolipidaemic effects of bioactive compounds from microalgae and marine micro-organisms. Int J Food Sci Technol. 2015;50(8):1705–1717. doi:10.1111/ijfs.2015.50.issue-8
   Web of Science ®Google Scholar
• Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Rondinone CM, Valverde AM, Lorenzo M. Protein–tyrosine phosphatase 1B–deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-α–induced insulin resistance. Diabetes. 2007;56(2):404–413. doi:10.2337/db06-0989
   PubMed Web of Science ®Google Scholar
• Møller NP, Iversen LF, Andersen HS, McCormack JG. Protein tyrosine phosphatases (PTPs) as drug targets: inhibitors of PTP-1B for the treatment of diabetes. Curr Opin Drug Discov Devel. 2000;3(5):527–540.
   PubMedGoogle Scholar
• Luo J, Xu Q, Jiang B, et al. Selectivity, cell permeability and oral availability studies of novel bromophenol derivative HPN as protein tyrosine phosphatase 1B inhibitor. Br J Pharmacol. 2018;175(1):140–153. doi:10.1111/bph.v175.1
   Web of Science ®Google Scholar
• Limbocker R, Chia S, Ruggeri FS, et al. Trodusquemine enhances Aβ 42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nat Commun. 2019;10(1):225. doi:10.1038/s41467-018-07699-5
   Web of Science ®Google Scholar
• Patil PD, Mahajan UB, Patil KR, et al. Past and current perspective on new therapeutic targets for Type-II diabetes. Drug Des Devel Ther. 2017;11:1567. doi:10.2147/DDDT.S133453
   PubMed Web of Science ®Google Scholar
• Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V. Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab. 2012;2012:1–9. doi:10.1155/2012/525093
   Google Scholar
• Bauerle KT, Harris C. Glucocorticoids and Diabetes. Mo Med. 2016;113(5):378.
   Google Scholar
• Stewart PM, Tomlinson JW. Selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both? Diabetes. 2009;58(1):14–15. doi:10.2337/db08-1404
   Web of Science ®Google Scholar
• Anagnostis P, Katsiki N, Adamidou F, et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism. 2013;62(1):21–33. doi:10.1016/j.metabol.2012.05.002
   PubMed Web of Science ®Google Scholar
• Nguyen ND, Le LT. Targeted proteins for diabetes drug design. Adv Nat Sci. 2012;3(1):013001.
   Google Scholar
• Tiwari N, Thakur AK, Kumar V, Dey A, Kumar V. Therapeutic targets for diabetes mellitus: an update. Clin Pharmacol Biopharm. 2014;3(1):1. doi:10.4172/2167-065X.1000117
   Google Scholar
• Liu JJ, Foo JP, Liu S, Lim SC. The role of fibroblast growth factor 21 in diabetes and its complications: a review from the clinical perspective. Diabetes Res Clin Pract. 2015;108(3):382–389. doi:10.1016/j.diabres.2015.02.032
   Web of Science ®Google Scholar
• Yuan D, Wu BJ, Henry A, Rye KA. Role of fibroblast growth factor 21 in gestational diabetes mellitus: a mini-review. Clin Endocrinol (Oxf). 2019;90(1):47–55. doi:10.1111/cen.13881
   Web of Science ®Google Scholar
• Domouzoglou EM, Maratos-Flier E. Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. Am J Clin Nutr. 2011;93(4):901S–5S. doi:10.3945/ajcn.110.001941
   Web of Science ®Google Scholar
• Kim JH, Bae KH, Choi YK, et al. Fibroblast growth factor 21 analogues LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabetes Obes Metab. 2015;17(2):161–169. doi:10.1111/dom.12408
   Web of Science ®Google Scholar
• Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J. 2013;37(5):315–325. doi:10.4093/dmj.2013.37.5.315
   PubMedGoogle Scholar
• Bonkowski MS, Sinclair DA. Slowing aging by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016;17(11):679. doi:10.1038/nrm.2016.93
   PubMed Web of Science ®Google Scholar
• Huynh FK, Hershberger KA, Hirschey MD. Targeting sirtuins for the treatment of diabetes. Diabetes Manag (Lond). 2013;3(3):245. doi:10.2217/dmt.13.6
   Google Scholar
• Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450(7170):712.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Chen H, Mak C, Zaky A, Pollock C, Saad S. SRT1720 attenuates obesity and insulin resistance but not liver damage in the offspring due to maternal and postnatal high-fat diet consumption. Am J Physiol Endocrinol Metab. 2018;315(2):E196–E203. doi:10.1152/ajpendo.00472.2017
   Web of Science ®Google Scholar
• Kim MJ, An HJ, Kim DH, et al. Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice. Bioorg Med Chem Lett. 2018;28(4):684–688. doi:10.1016/j.bmcl.2018.01.021
   Web of Science ®Google Scholar
• Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016;23(1):87. doi:10.1186/s12929-016-0303-y
   PubMed Web of Science ®Google Scholar
• Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392–2401. doi:10.1016/j.jacc.2018.03.002
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465. doi:10.1038/nrd4275
   PubMed Web of Science ®Google Scholar
• Akash MS, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in the development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–110. doi:10.1002/jcb.26174
   PubMed Web of Science ®Google Scholar
• Delporte C. Recent advances in the potential clinical application of ghrelin in obesity. J Obes. 2012;20:2012.
   Google Scholar
• McCallum RW, Lembo A, Esfandyari T, et al. TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25(11):e705–17. doi:10.1111/nmo.2013.25.issue-11
   PubMed Web of Science ®Google Scholar
• Pradhan G, Wu CS, Lee JH, et al. Obestatin stimulates glucose-induced insulin secretion through ghrelin receptor GHS-R. Sci Rep. 2017;7(1):979. doi:10.1038/s41598-017-00888-0
   Web of Science ®Google Scholar
• Cao J, Zhou Y, Peng H, et al. Targeting Acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem. 2011;286(48):41838–41851. doi:10.1074/jbc.M111.245456
   PubMed Web of Science ®Google Scholar
• Qian Y, Wertheimer SJ, Ahmad M, et al. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. J Med Chem. 2011;54(7):2433–2446. doi:10.1021/jm101580m
   PubMed Web of Science ®Google Scholar
• Waring MJ, Birch AM, Birtles S, et al. Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1–the discovery of AZD2353. MedChemComm. 2013;4(1):159–164. doi:10.1039/C2MD20190A
   Web of Science ®Google Scholar
• Peguero JG, Arenas I, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc Med. 2014;24(6):232–240. doi:10.1016/j.tcm.2014.06.002
   PubMed Web of Science ®Google Scholar
• Qiu Q, Zhang F, Zhu W, Wu J, Liang M. Copper in diabetes mellitus: a meta-analysis and systematic review of plasma and serum studies. Biol Trace Elem Res. 2017;177(1):53–63. doi:10.1007/s12011-016-0877-y
   PubMed Web of Science ®Google Scholar
• Frizzell N, Baynes JW. Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma. Clin Chem Lab Med. 2014;52(1):69–75. doi:10.1515/cclm-2012-0881
   Web of Science ®Google Scholar
• Gong D, Lu J, Chen X, et al. A copper (II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-β activation in the kidneys of rats used as a model of diabetes. Diabetologia. 2008;51(9):1741–1751. doi:10.1007/s00125-008-1088-7
   Web of Science ®Google Scholar
• Tarantino G, Porcu C, Arciello M, Andreozzi P, Balsano C. Prediction of carotid intima–media thickness in obese patients with low prevalence of comorbidities by serum copper bioavailability. J Gastroenterol Hepatol. 2018;33(8):1511–1517. doi:10.1111/jgh.2018.33.issue-8
   Web of Science ®Google Scholar
• Lu J, Gong D, Choong SY, et al. Copper (II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia. 2010;53(6):1217–1226. doi:10.1007/s00125-010-1698-8
   Web of Science ®Google Scholar
• JS Cooper G. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem. 2012;19(17):2828–2860. doi:10.2174/092986712800609715
   Web of Science ®Google Scholar